Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/JBM.S42669 http://scihub22266oqcxt.onion/10.2147/JBM.S42669 C4562652!4562652!26366108     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26366108.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Blood+Med 2015 ; 6 (ä): 245-55 Nephropedia Template TP {{tp|p=26366108|t=2015. Emerging and future therapies for hemophilia |pdf=|usr=}}{{26366108}} gab.com Text Emerging and future therapies for hemophilia JO: J Blood Med http://www.kidney.de/pget.php?&tw=1&pmid=26366108 #FOAvip The evolution of care in hemophilia is a remarkable story. Over the last 60 years, advances in protein purification, protein chemistry, donor screening, viral inactivation, gene sequencing, gene cloning, and recombinant protein production have dramatically enhanced the treatment and lives of patients with hemophilia. Recent efforts have produced enhanced half-life (EHL) clotting factors to better support prophylaxis and decrease the frequency of infusions. Medical needs remain in the areas of alternate modes of administration to decrease the need for venous access, better treatment, and prophylaxis for patients who form antibodies to clotting factors, and ultimately a cure of the underlying genetic defect. In this brief review, the authors summarize data on EHL clotting factors, introduce agents whose mode of action is not clotting factor replacement, and list current gene therapy efforts. Twit Text FOAVip Emerging and future therapies for hemophilia ????J Blood Med http://www.kidney.de/pget.php?&tw=1&pmid=26366108 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26366108 #FOAvip English Wikipedia <ref>{{Cite pmid|26366108}}</ref> Emerging and future therapies for hemophilia #MMPMID26366108 Carr ME; Tortella BJ J Blood Med 2015[]; 6 (ä): 245-55 PMID26366108show ga The evolution of care in hemophilia is a remarkable story. Over the last 60 years, advances in protein purification, protein chemistry, donor screening, viral inactivation, gene sequencing, gene cloning, and recombinant protein production have dramatically enhanced the treatment and lives of patients with hemophilia. Recent efforts have produced enhanced half-life (EHL) clotting factors to better support prophylaxis and decrease the frequency of infusions. Medical needs remain in the areas of alternate modes of administration to decrease the need for venous access, better treatment, and prophylaxis for patients who form antibodies to clotting factors, and ultimately a cure of the underlying genetic defect. In this brief review, the authors summarize data on EHL clotting factors, introduce agents whose mode of action is not clotting factor replacement, and list current gene therapy efforts. äEmerging and future therapies for hemophilia (epmc).pdf DeepDyve Pubget Overpricing